1.
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2018. Ca-a Cancer Journal for Clinicians.
2018;68(1):7-30.
2.
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China,
2015. CA Cancer J Clin. 2016;66(2):115-32.
3.
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H,
et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries
in 2012. Eur J Cancer. 2013;49(6):1374-403.
4.
Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al. EAU guidelines
on prostate cancer. Eur Urol. 2008;53(1):68-80.
5.
Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG
Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with
Curative Intent. Eur Urol. 2017;71(4):618-29.
6.
Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al.
EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and
Castration-Resistant Prostate Cancer. Eur Urol. 2014;65(2):467-79.
7.
Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG
Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant
Prostate Cancer. Eur Urol. 2017;71(4):630-42.
8.
Ahmad K. New progress in treatment of hormone-refractory prostate cancer. Lancet Oncol.
2004;5(12):706.
9.
Petrylak DP. Future directions in the treatment of androgen-independent prostate cancer.
Urology. 2005;65(6 Suppl):8-12.
10.
Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, et al. Maintenance
of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant
tumor growth. Cancer Res. 2008;68(11):4447-54.
11.
Seruga B, Ocana A, Tannock IF. Drug resistance in metastatic castration-resistant
prostate cancer. Nat Rev Clin Oncol. 2011;8(1):12-23.
12.
Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer
population: a systematic review. Int J Clin Pract. 2011;65(11):1180-92.
13.
Basch E, Loblaw DA, Oliver TK, Carducci M, Chen RC, Frame JN, et al. Systemic Therapy
in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical
Oncology and Cancer Care Ontario Clinical Practice Guideline. J Clin Oncol. 2014;32(30):3436-U133.
14.
de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone
plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer
progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147-54.
15.
Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus
prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival
in the TAX 327 study. J Clin Oncol. 2008;26(2):242-5.
16.
Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternberg CN, et al. Abiraterone
acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with
metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival
analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol.
2015;16(2):152-60.
17.
De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone
and Increased Survival in Metastatic Prostate Cancer. N Engl J Med. 2011;364(21):1995-2005.
18.
Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone
in Metastatic Prostate Cancer without Previous Chemotherapy. N Engl J Med. 2013;368(2):138-48.
19.
Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Antitumour
activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet.
2010;375(9724):1437-46.
20.
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival
with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187-97.
21.
Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide
in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Extended
Analysis of the Phase 3 PREVAIL Study. Eur Urol. 2017;71(2):151-4.
22.
Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a Second-Generation
Antiandrogen for Treatment of Advanced Prostate Cancer. Science. 2009;324(5928):787-90.
23.
Beer TM, Tombal B. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
REPLY. N Engl J Med. 2014;371(18):1755-6.
24.
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T
Immunotherapy for Castration-Resistant Prostate Cancer. N Engl J Med. 2010;363(5):411-22.
25.
Kawalec P, Paszulewicz A, Holko P, Pilc A. Sipuleucel-T immunotherapy for castration-resistant
prostate cancer. A systematic review and meta-analysis. Arch Med Sci. 2012;8(5):767-75.
26.
Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved
Therapeutic Cancer Vaccine. Clin Cancer Res. 2011;17(11):3520-6.
27.
Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, et al.
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015)
in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin
Oncol. 2006;24(19):3089-94.
28.
Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, et al. Alpha Emitter
Radium-223 and Survival in Metastatic Prostate Cancer. N Engl J Med. 2013;369(3):213-23.
29.
Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, et al. Effect
of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant
prostate cancer and bone metastases: results from a phase 3, double-blind, randomised
trial. Lancet Oncol. 2014;15(7):738-46.
30.
Saad F, Carles J, Gillessen S, Heidenreich A, Heinrich D, Gratt J, et al. Radium-223
and concomitant therapies in patients with metastatic castration-resistant prostate
cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet
Oncol. 2016;17(9):1306-16.
31.
Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, et al. Denosumab and bone-metastasis-free
survival in men with castration-resistant prostate cancer: results of a phase 3, randomised,
placebo-controlled trial. Lancet. 2012;379(9810):39-46.
32.
Smith MR, Coleman RE, Klotz L, Pittman K, Milecki P, Ng S, et al. Denosumab for the
prevention of skeletal complications in metastatic castration-resistant prostate cancer:
comparison of skeletal-related events and symptomatic skeletal events. Ann Oncol.
2015;26(2):368-74.
33.
Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN. Clinical activity
of abiraterone acetate in patients with metastatic castration-resistant prostate cancer
progressing after enzalutamide. Ann Oncol. 2013;24(7):1802-7.
34.
Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone
acetate for treatment of metastatic castration-resistant prostate cancer: final overall
survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase
3 study. Lancet Oncol. 2012;13(10):983-92.
35.
Sonpavde G, Bhor M, Hennessy D, Bhowmik D, Shen LJ, Nicacio L, et al. Sequencing of
Cabazitaxel and Abiraterone Acetate After Docetaxel in Metastatic Castration-Resistant
Prostate Cancer: Treatment Patterns and Clinical Outcomes in Multicenter Community-Based
US Oncology Practices. Clin Genitourin Cancer. 2015;13(4):309-18.
36.
Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation
therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene.
2013;32(49):5501-11.
37.
Boudadi K, Antonarakis ES. Resistance to Novel Antiandrogen Therapies in Metastatic
Castration-Resistant Prostate Cancer. Clin Med Insights Oncol. 2016;10(Suppl 1):1-9.
38.
Luo J, Attard G, Balk SP, Bevan C, Burnstein K, Cato L, et al. Role of Androgen Receptor
Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants
Meeting. Eur Urol. 2018;73(5):715-23.
39.
Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational
landscape of lethal castration-resistant prostate cancer. Nature. 2012;487(7406):239-43.
40.
Giacinti S, Poti G, Roberto M, Macrini S, Bassanelli M, Di Pietro F, et al. Molecular
Basis of Drug Resistance and Insights for New Treatment Approaches in mCRPC. Anticancer
Res. 2018;38(11):6029-39.
41.
Sumanasuriya S, De Bono J. Treatment of Advanced Prostate Cancer-A Review of Current
Therapies and Future Promise. Cold Spring Harb Perspect Med. 2018;8(6).
42.
Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative
clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215-28.
43.
Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al. DNA-Repair
Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med. 2015;373(18):1697-708.
44.
Reichert Z, Carneiro BA, Daignault-Newton S, Sullivan A, Feng FYC, Morgan TM, et al.
A randomized phase II trial of abiraterone, olaparib or abiraterone plus olaparib
in patients with metastatic castration-resistant prostate cancer with DNA repair defects.
J Clin Oncol. 2017;35.
45.
Goodall J, Mateo J, Yuan W, Mossop H, Porta N, Miranda S, et al. Circulating Cell-Free
DNA to Guide Prostate Cancer Treatment with PARP Inhibition. Cancer Discov. 2017;7(9):1006-17.
46.
Rescigno P, Chandler R, de Bono J. Relevance of poly (ADP-ribose) polymerase inhibitors
in prostate cancer. Curr Opin Support Palliat Care. 2018;12(3):339-43.
47.
Baciarello G, Gizzi M, Fizazi K. Advancing therapies in metastatic castration-resistant
prostate cancer. Expert Opin Pharmacother. 2018;19(16):1797-804.
48.
Hansen AR, Massard C, Ott PA, Haas NB, Lopez JS, Ejadi S, et al. Pembrolizumab for
advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Ann Oncol. 2018;29(8):1807-13.
49.
McNeel DG, Eickhoff JC, Jeraj R, Staab MJ, Straus J, Rekoske B. DNA vaccine with pembrolizumab
to elicit antitumor responses in patients with metastatic, castration-resistant prostate
cancer (mCRPC). J Clin Oncol. 2017;35(7).
50.
Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I
study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors:
safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol.
2010;28(19):3167-75.
51.
Taube JM, Klein A, Brahmer JR, Xu HY, Pan XY, Kim JH, et al. Association of PD-1,
PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response
to Anti-PD-1 Therapy. Clin Cancer Res. 2014;20(19):5064-74.
52.
Vaishampayan UN. Changing face of metastatic prostate cancer: the law of diminishing
returns holds true. Curr Opin Oncol. 2017;29(3):196-200.
53.
Powles T, Fizazi K, Gillessen S, Drake CG, Rathkopf DE, Narayanan S, et al. A phase
III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients
with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2017;35.
54.
Fong L, Morris M, Armstrong A, Petrylak D, Vaishampayan U, Alva A, et al. A phase
Ib trial to study the safety and tolerability of atezolizumab with radium-223 dichloride
in patients with metastatic castrate-resistant prostate cancer (mCRPC). Cancer Res.
2017;77.
55.
Kim JW, Shaffer DR, Massard C, Powles T, Harshman LC, Braiteh FS. A phase Ia study
of safety and clinical activity of atezolizumab (atezo) in patients (pts) with metastatic
castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2018;36(6).
56.
Ferdinandus J, Violet J, Sandhu S, Hofman MS. Prostate-specific membrane antigen theranostics:
therapy with lutetium-177. Curr Opin Urol. 2018;28(2):197-204.
57.
Ahmadzadehfar H, Rahbar K, Kurpig S, Bogemann M, Claesener M, Eppard E, et al. Early
side effects and first results of radioligand therapy with Lu-177-DKFZ-617 PSMA of
castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res. 2015;5:1-8.
58.
Ahmadzadehfar H, Eppard E, Kurpig S, Fimmers R, Yordanova A, Schlenkhoff CD, et al.
Therapeutic response and side effects of repeated radioligand therapy with Lu-177-PSMA-DKFZ-617
of castrate-resistant metastatic prostate cancer. Oncotarget. 2016;7(11):12477-88.
59.
Ahmadzadehfar H, Wegen S, Yordanova A, Fimmers R, Kurpig S, Eppard E, et al. Overall
survival and response pattern of castration-resistant metastatic prostate cancer to
multiple cycles of radioligand therapy using [Lu-177]Lu-PSMA-617. Eur J Nucl Med Mol
Imaging. 2017;44(9):1448-54.
60.
Rahbar K, Bogeman M, Yordanova A, Eveslage M, Schafers M, Essler M, et al. Delayed
response after repeated Lu-177-PSMA-617 radioligand therapy in patients with metastatic
castration resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45(2):243-6.
61.
de Bono J, Bracarda S, Chi K, Massard C, Hidalgo DO, Sandhu S, et al. Randomized phase
III trial of ipatasertib vs. placebo, plus abiraterone and prednisone/prednisolone,
in men with asymptomatic or mildly symptomatic previously untreated metastatic castrate-resistant
prostate cancer (mCRPC). Ann Oncol. 2017;28.
62.
Hussain M, Carducci MA, Slovin S, Cetnar J, Qian J, McKeegan EM, et al. Targeting
DNA repair with combination veliparib (ABT-888) and temozolomide in patients with
metastatic castration-resistant prostate cancer. Invest New Drugs. 2014;32(5):904-12.
63.
Hussain M, Daignault S, Twardowski P, Albany C, Stein MN, Kunju LP, et al. Abiraterone
plus prednisone (Abi) plus /- veliparib (Vel) for patients (pts) with metastatic castration
resistant prostate cancer (CRPC): NCI 9012 updated clinical and genomics data. J Clin
Oncol. 2017;35.
64.
Pahuja S, Appleman LJ, Belani CP, Chen A, Chu E, Beumer JH, et al. Preliminary activity
of veliparib (V) in BRCA2-mutated metastatic castration-resistant prostate cancer
(mCRPC). J Clin Oncol. 2015;33(7).
65.
Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, et al. Randomized, Double-Blind,
Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic
Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.
J Clin Oncol. 2017;35(1):40-+.
66.
de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating
tumor cells predict survival benefit from treatment in metastatic castration-resistant
prostate cancer. Clin Cancer Res. 2008;14(19):6302-9.
67.
Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance
to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371(11):1028-38.
68.
Armstrong AJ, Saad F, Phung D, Dmuchowski C, Shore ND, Fizazi K, et al. Clinical Outcomes
and Survival Surrogacy Studies of Prostate-Specific Antigen Declines Following Enzalutamide
in Men with Metastatic Castration-Resistant Prostate Cancer Previously Treated with
Docetaxel. Cancer. 2017;123(12):2303-11.
69.
Chi KN, Kheoh T, Ryan CJ, Molina A, Bellmunt J, Vogelzang NJ, et al. A prognostic
index model for predicting overall survival in patients with metastatic castration-resistant
prostate cancer treated with abiraterone acetate after docetaxel. Ann Oncol. 2016;27(3):454-60.
70.
Liu Y, Zhang N, Bao GY, Huang YB, Ji BY, Wu YL, et al. Predictors of depressive symptoms
in college students: A systematic review and meta-analysis of cohort studies. J Affect
Disorders. 2019;244:196-208.
71.
Begum M, Lewison G, Lawler M, Sullivan R. Mapping the European cancer research landscape:
An evidence base for national and Pan-European research and funding. Eur J Cancer.
2018;100:75-84.
72.
Cox EB, Berry WR. Ldh as a Predictor of Chemotherapy Response and Survival in Hormone
Refractory Metastatic Prostate-Cancer (Hrpc). P Am Assoc Canc Res. 1979;20(Mar):414-.
73.
Popkirov S, Jungilligens J, Schlegel U, Wellmer J. Research on dissociative seizures:
A bibliometric analysis and visualization of the scientific landscape. Epilepsy Behav.
2018;83:162-7.
74.
Mohler JL, Armstrong AJ, Bahnson RR, D'Amico AV, Davis BJ, Eastham JA, et al. Prostate
Cancer, Version 1.2016 Featured Updates to the NCCN Guidelines. J Natl Compr Cancer
Netw. 2016;14(1):19-30.
75.
Klein J, von dem Knesebeck O. Socioeconomic inequalities in prostate cancer survival:
A review of the evidence and explanatory factors. Soc Sci Med. 2015;142:9-18.
76.
Rebbeck TR. Prostate Cancer Genetics: Variation by Race, Ethnicity, and Geography.
Semin Radiat Oncol. 2017;27(1):3-10.
77.
Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, et al. Prevention
and early detection of prostate cancer. Lancet Oncol. 2014;15(11):e484-92.
78.
Fabiani R, Minelli L, Bertarelli G, Bacci S. A Western Dietary Pattern Increases Prostate
Cancer Risk: A Systematic Review and Meta-Analysis. Nutrients. 2016;8(10).
79.
McGuire S. World Cancer Report 2014. Geneva, Switzerland: World Health Organization,
International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr. 2016;7(2):418-9.
80.
Zhang Y, Porter AL, Hu ZY, Guo Y, Newman NC. "Term clumping" for technical intelligence:
A case study on dye-sensitized solar cells. Technol Forecast Soc. 2014;85:26-39.
81.
Glanzel W. National characteristics in international scientific co-authorship relations.
Scientometrics. 2001;51(1):69-115.
82.
Tahamtan I, Afshar AS, Ahamdzadeh K. Factors affecting number of citations: a comprehensive
review of the literature. Scientometrics. 2016;107(3):1195-225.
83.
Franceschet M, Costantini A. The effect of scholar collaboration on impact and quality
of academic papers. J Informetr. 2010;4(4):540-53.
84.
Chen HQ, Wang XP, He L, Chen P, Wan YH, Yang LY, et al. Chinese energy and fuels research
priorities and trend: A bibliometric analysis. Renew Sust Energ Rev. 2016;58:966-75.
85.
Acosta M, Coronado D, Ferrandiz E, Leon MD. Regional Scientific Production and Specialization
in Europe: The Role of HERD. Eur Plan Stud. 2014;22(5):949-74.
86.
Ebadi A, Schiffauerova A. How to boost scientific production? A statistical analysis
of research funding and other influencing factors. Scientometrics. 2016;106(3):1093-116.
87.
Nag S, Yang H, Buccola S, Ervin D. Productivity and financial support in academic
bioscience. Appl Econ. 2013;45(19):2817-26.
88.
Read KB, Sheehan JR, Huerta MF, Knecht LS, Mork JG, Humphreys BL, et al. Sizing the
Problem of Improving Discovery and Access to NIH-Funded Data: A Preliminary Study.
PLoS One. 2015;10(7).
91.
DeAngelis CD. The influence of money on medical science. JAMA. 2006;296(8):996-8.
92.
Moses H, Dorsey ER, Matheson DHM, Thier SO. Financial anatomy of biomedical research.
Jama-J Am Med Assoc. 2005;294(11):1333-42.
93.
Potter GA, Hardcastle IR, Jarman M. A convenient, large-scale synthesis of abiraterone
acetate [3 beta-acetoxy-17-(3-pyridyl)androsta-5,16-diene], a potential new drug for
the treatment of prostate cancer. Org Prep Proced Int. 1997;29(1):123-8.
94.
Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in
biomedical research - A systematic review. Jama-J Am Med Assoc. 2003;289(4):454-65.
95.
Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and
research outcome and quality: systematic review. BMJ-British Medical Journal. 2003;326(7400):1167-70b.
96.
Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research
outcome. Cochrane Database Syst Rev. 2017(2).
97.
Flacco ME, Manzoli L, Boccia S, Capasso L, Aleksovska K, Rosso A, et al. Head-to-head
randomized trials are mostly industry sponsored and almost always favor the industry
sponsor. J Clin Epidemiol. 2015;68(7):811-20.
98.
Rothman DJ, McDonald WJ, Berkowitz CD, Chimonas SC, DeAngelis CD, Hale RW, et al.
Professional Medical Associations and Their Relationships With Industry A Proposal
for Controlling Conflict of Interest. Jama-J Am Med Assoc. 2009;301(13):1367-72.
99.
Kahn JO, Cherng DW, Mayer K, Murray H, Lagakos S, Team I. Evaluation of HIV-1 immunogen,
an immunologic modifier, administered to patients infected with HIV having 300 to
549 x 10(6)/L CD4 cell counts - A randomized controlled trial. Jama-J Am Med Assoc.
2000;284(17):2193-202.
100.
Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal
toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis
and rheumatoid arthritis - The CLASS study: A randomized controlled trial. Jama-J
Am Med Assoc. 2000;284(10):1247-55.
101.
Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison
of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid
arthritis. N Engl J Med. 2000;343(21):1520-8.
102.
Curfman GD, Morrissey S, Drazen JM. Expression of concern reaffirmed. N Engl J Med.
2006;354(11):1193-.
103.
Gibson L. GlaxoSmidiKline to publish clinical trials after US lawsuit. Brit Med J.
2004;328(7455):1513-.
104.
Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications
related to rofecoxib - A case study of industry documents from rofecoxib litigation.
Jama-J Am Med Assoc. 2008;299(15):1800-12.
105.
Chen K, Yao Q, Sun J, He ZF, Yao L, Liu ZY. International publication trends and collaboration
performance of China in healthcare science and services research. Isr J Health Policy
Res. 2016;5:1.
106.
Wu YQ, Wan YH, Zhang FZ. Characteristics and Trends of C-H Activation Research: A
Review of Literature. Curr Org Synth. 2018;15(6):781-92.
107.
Bao G, Fang H, Chen L, Wan Y, Xu F, Yang Q, et al. Soft Robotics: Academic Insights
and Perspectives Through Bibliometric Analysis. Soft Robot. 2018;5(3):229-41.
108.
Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus
prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J
Med. 2004;351(15):1502-12.
109.
Shore ND. Darolutamide (ODM-201) for the treatment of prostate cancer. Expert Opin
Pharmacother. 2017;18(9):945-52.
110.
Rathkopf DE, Antonarakis ES, Shore ND, Tutrone RF, Alumkal JJ, Ryan CJ, et al. Safety
and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant
Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone. Clin Cancer
Res. 2017;23(14):3544-51.
111.
Porter AL, Garner J, Newman NC, Carley SF, Youtie J, Kwon S, et al. National nanotechnology
research prominence. Technol Anal Strateg. 2019;31(1):25-39.
112.
Carley SF, Newman NC, Porter AL, Garner JG. An indicator of technical emergence. Scientometrics.
2018;115(1):35-49.
113.
Garner J, Carley S, Porter AL, Newman NC. Technological Emergence Indicators Using
Emergence Scoring. Portl Int Conf Manag. 2017.
114.
Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B, et al. Radiation
dosimetry and first therapy results with a I-124/I-131-labeled small molecule (MIP-1095)
targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014;41(7):1280-92.
115.
Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, et al.
Phase II Study of Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal
Antibody J591 for Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res.
2013;19(18):5182-91.
116.
Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, et al. Ga-68-
and Lu-177-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and
First Proof-of-Concept Human Studies. J Nucl Med. 2015;56(8):1169-76.
117.
Kratochwil C, Bruchertseifer F, Rathke H, Bronzel M, Apostolidis C, Weichert W, et
al. Targeted alpha-Therapy of Metastatic Castration-Resistant Prostate Cancer with
Ac-225-PSMA-617: Dosimetry Estimate and Empiric Dose Finding. J Nucl Med. 2017;58(10):1624-31.
118.
Yordanova A, Becker A, Eppard E, Kurpig S, Fisang C, Feldmann G, et al. The impact
of repeated cycles of radioligand therapy using [Lu-177] Lu-PSMA-617 on renal function
in patients with hormone refractory metastatic prostate cancer. Eur J Nucl Med Mol
Imaging. 2017;44(9):1473-9.
119.
Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schafers M, Essler M, et al.
German Multicenter Study Investigating Lu-177-PSMA-617 Radioligand Therapy in Advanced
Prostate Cancer Patients. J Nucl Med. 2017;58(1):85-90.
120.
Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, et al. Liquid
biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer.
2017;17(4):223-38.
121.
Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the
management of cancer. Nat Rev Clin Oncol. 2017;14(9):531-48.
122.
Annala M, Vandekerkhove G, Khalaf D, Taavitsainen S, Beja K, Warner EW, et al. Circulating
Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate
Cancer. Cancer Discov. 2018;8(4):444-57.
123.
Mateo J, Boysen G, Barbieri CE, Bryant HE, Castro E, Nelson PS, et al. DNA Repair
in Prostate Cancer: Biology and Clinical Implications. Eur Urol. 2017;71(3):417-25.
124.
Cheng HH, Pritchard CC, Boyd T, Nelson PS, Montgomery B. Biallelic Inactivation of
BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer. Eur Urol.
2016;69(6):992-5.
125.
Giacinti S PG, Roberto M, Macrini S, Bassanelli M, DI Pietro F, Aschelter AM, Ceribelli
A, Ruggeri EM, Marchetti P. Molecular Basis of Drug Resistance and Insights for New
Treatment Approaches in mCRPC. Anticancer Res. 2018;38(11):10.
126.
van Soest RJ, van Royen ME, de Morree ES, Moll JM, Teubel W, Wiemer EAC, et al. Cross-resistance
between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug
sequence choices in metastatic castration-resistant prostate cancer. Eur J Cancer.
2013;49(18):3821-30.